Competition and R&D Financing Decisions: Theory and Evidence from the Biopharmaceutical Industry

Working Paper: NBER ID: w20903

Authors: Richard T. Thakor; Andrew W. Lo

Abstract: How does competition affect innovation and how it is financed in R&D-intensive firms? We study the interaction between competition, R&D investments, and the financing choices of such firms using data on biopharmaceutical firms. To motivate the empirical hypotheses, we develop a model for such firms in which their capital structure and amounts invested in R&D as well as existing assets are all determined in response to the degree of competition in the industry. The key predictions are that, as competition increases, such firms will: (1) increase R&D investment relative to investment in assets-in-place that support existing products; (2) carry more cash and maintain less net debt; and (3) experience declining betas but greater total stock return volatility due to higher idiosyncratic risk. While the focus is on the biopharmaceutical industry, the results are broadly applicable to other R&Dintensive industries as well. We provide empirical support for these predictions. In order to deal with the endogeneity issue introduced by the fact that a firm's R&D investments and the product-market competition it faces influence each other, we provide further evidence through a differences-in-differences analysis.

Keywords: competition; R&D financing; biopharmaceutical industry; innovation; capital structure

JEL Codes: D82; D83; G31; G32; L11; L15; L25; L65


Causal Claims Network Graph

Edges that are evidenced by causal inference methods are in orange, and the rest are in light blue.


Causal Claims

CauseEffect
increased competition (L13)reduced investments in assets-in-place (G31)
increased competition (L13)increased investments in R&D (O39)
increased competition (L13)increased cash holdings (G32)
increased competition (L13)reduced net debt (G32)
increased competition (L13)decline in firm's beta (G32)
increased competition (L13)increased idiosyncratic risk (G19)
increased competition (L13)greater total stock return volatility (G17)

Back to index